What this covers

Dinakar Singh, founder of the family office Axon and formerly of the hedge fund TPG-Axon, tells the story of his daughter's diagnosis with spinal muscular atrophy, released for Father's Day. He explains the biology: a missing key gene, a defective backup gene, and a number of backup copies that decides whether a patient dies within weeks or lives 10 to 15 years. Most patients die of pneumonia or choking, not of the muscle disease itself. He also describes the daily therapy that slowed his daughter's decline.

The middle of the conversation is the method. His team ran three shots on goal at once: antisense oligonucleotides at Cold Spring Harbor, small-molecule screening with PTC Therapeutics, and gene therapy with AveXis. All three became approved drugs. Because academia will not develop drugs, they built a virtual company with hired scientists and an advisory brain trust, and offered companies free compound testing while letting them keep the IP. Other threads include the favorable therapeutic window, an FDA agreement to use a natural history study instead of placebo, and a deliberate show of momentum to FDA, NIH, and Congress.

The later sections are more contested. Singh argues that funding follows how familiar a disease is, and that modest coordinated money in early preclinical work could move a disease far enough to interest companies. He regrets that funders did not restrict prices, since launch prices ran from $750,000 to $800,000 a year. He notes that Columbia University faced a working-capital problem buying doses, and describes a family in Uzbekistan who raised $400,000 but could not obtain treatment. He also says SMA could serve as a testbed for muscle-regeneration drugs.

Sharpest takeaway

Singh argues that a parent with private capital can compress rare-disease drug development by running many approaches in parallel as a virtual company, but that the wider system needs early-stage structures, collaboration, and pricing limits to make such speed and access normal.

  • Parallel, virtual-company execution with free compound testing and political momentum produced the fastest FDA approval of an SMA drug
  • Rare-disease research stalls because grants, academia, and companies reward IP and familiar diseases, not solving the disease
  • Drug pricing of $750,000 to $2 million a year leaves children without access, including across borders

The claims · ranked60 claims · weighted by value

This asset isn't compiled yet

You're seeing its claims, ranked. Compile it to build the argument threads, weight them, and check each claim against your library — the full view.

0.80

The team pursued three shots on goal, antisense oligonucleotides at Cold Spring Harbor, small molecules screened with PTC Therapeutics, and gene therapy with AveXis, and all three became approved SMA drugs.

factualhigh valueestablishednovelty 2/4durability 4/4· Dinakar

“Today we have all three as approved drugs. So the first was that Biogen sell, the second was gene therapy with AveXis, and the third is Roche”

0.78

A child who receives the drug close to diagnosis will never show symptoms of SMA.

forecasthigh valueestablishednovelty 3/4durability 3/4· Dinakar

“So a child born and getting the drug close to diagnosis will never show symptoms.”

0.75

Maintaining the daughter's strength through daily physical therapy, diet, exercise, and a warm-water therapy pool slowed the cycle of weakness that otherwise worsens SMA, but progression still caused spinal fusion, hip problems, and repeated pneumonia until the drug was available.

causalhigh valueestablishednovelty 2/4durability 3/4· Dinakar

“part of the problem is it's circular. You're weak, you can't exercise and stretch your muscles and bones, so they keep getting weaker and weaker”

0.73

The FDA agreed to replace placebo-controlled trials with a natural history study, in which the team paid for patient care for several years to build a log of disease progression, and trial results were compared to that log, saving children who would otherwise have been on placebo.

causalhigh valuecontestednovelty 3/4durability 3/4· Dinakar

“we basically paid for people's care for a handful of years so that we could have a log of what the natural progression of the disease was and use that as our placebo.”

0.73

The family made the case to FDA, NIH, senators, and congressmen that a parent's grief alone was insufficient, so they paired emotion with the argument that the disease was fixable, and they used a coordinated show of momentum to speed decisions.

causalhigh valuecontestednovelty 3/4durability 3/4· Dinakar

“a parent with tears on their face doesn't get very far”

0.73

Singh argues that the early preclinical stage of rare disease research costs relatively little compared with later clinical development, so modest public or institutional funding could move a disease far enough for companies to take interest.

factualhigh valuecontestednovelty 3/4durability 3/4· Dinakar

“that early stage doesn't cost that much either. It's later on that you really start going down many rabbit holes.”

0.73

SMA results from a missing key gene that makes a protein needed by muscles and nerves; everyone has a backup gene that makes a defective protein, and the number of backup copies and the residual protein level determine whether a patient dies within weeks or survives 10 to 15 years.

causalhigh valueestablishednovelty 2/4durability 4/4· Dinakar

“depending on how many backup genes you have and how little or more than a little protein you have, you might die within a few weeks or you might die within 10, 15 years.”

0.70

A Goldman Sachs analyst's family in Uzbekistan raised $400,000 through community fundraising for a diagnosed child, but no clinic would accept the money, and treatment abroad was blocked by legal and regulatory barriers, leaving the child at risk of death or unnecessary suffering.

factualhigh valueestablishednovelty 2/4durability 2/4· Dinakar

“the family had gone around through supermarket fundraising, meaning cans and signs in town, raised $400,000 to get her treated. And they couldn't find someone to take the money”

0.68

Because SMA patients have a defective backup gene factory, it is easier to crank up and improve that backup than to replace a gene that is entirely missing, which is why the team judged it a more tractable target.

causalhigh valueestablishednovelty 2/4durability 3/4· Dinakar

“having a backup factory in place that you could try and crank up and fix to make a bit better is a wholly easier challenge than having to replace something that simply went missing in the first place”

0.68

Gene therapy using viral vectors works only in very small children because the viral dose needed grows with body size, and at larger sizes the dose becomes toxic.

causalhigh valueestablishednovelty 2/4durability 3/4· Dinakar

“gene therapy is great, but only works for very little kids. Essentially in gene therapy you're taking viruses, you're bringing protein in your body and when you're large, that amount of virus will kill you.”

0.68

Singh regrets that the funders did not impose price restrictions on rare-disease drugs at the outset, arguing that $1 to $2 million a year is excessive and that windfall profits should fund charity care.

normativehigh valuecontestednovelty 2/4durability 3/4· Dinakar

“I wish when we had put all the money in, we had put in restrictions on what companies could eventually charge because a million to 2 million bucks a year is bonkers.”

0.68

Government and institutions like Jackson Labs could fund a few diseases at a time with modest, coordinated amounts of money and a clear game plan, because most patient groups need a plan more than random grants.

normativehigh valuecontestednovelty 2/4durability 3/4· Dinakar

“Where a few diseases are picked at a time and a modest amount of money is put in or coordinated so that you actually end up having a game plan.”

0.68

SMA patients typically do not die from the muscle disease itself but from complications such as pneumonia, asphyxiation, or choking, which are the result of progressive weakness.

factualhigh valueestablishednovelty 2/4durability 3/4· Dinakar

“no one dies of SMA. It just makes you really weak. And then something gets you, whether it's asphyxiation or it's choking or it's pneumonia”

0.68

Clinical trials of muscle-targeted drugs in elderly patients with age-related weakness are very difficult because decline is steep, making moderate effects hard to detect, and the same challenge affects Alzheimer's trials.

factualhigh valueestablishednovelty 2/4durability 3/4· Dinakar Singh

“clinical trials, and this is the problem with Alzheimer's, are very, very challenging in elderly, degenerating patients”

0.66

SMA therapy had a favorable therapeutic window because the range of the target protein across people is so wide that you can almost not have too much, which reduces the toxicity and undershoot problems that narrow-window drugs suffer.

causalhigh valuecontestednovelty 3/4durability 3/4· Dinakar

“there's such a massive range of this protein in the body that's pretty clear that you almost can't have too much.”

0.63

Testing showed that existing FDA-approved drugs would have some impact but none would be effective enough without toxicity, which motivated the decision to pursue novel modalities rather than repurposing.

causalhigh valueestablishednovelty 2/4durability 2/4· Dinakar

“the existing FDA approved drugs, some would have some impact, but none would be good enough and you'd have toxicity issues”

0.63

Biogen bought the antisense drug the team helped develop through Cold Spring Harbor and Ionis and became first to market, charging about $750,000 a year, and SMA drugs now generate billions as a top-three revenue product for Roche, Novartis, and Biogen.

factualhigh valueestablishednovelty 2/4durability 2/4· Dinakar

“they charged I think $750,000 a year for it. I think it's one of the top three drugs pulling in I think four or five billion dollars in revenue.”

0.63

When the first SMA drug launched at $800,000 a year, Columbia faced a working capital problem because buying doses for its patients would have cost tens of millions of dollars that were not in its budget.

factualhigh valueestablishednovelty 2/4durability 2/4· Dinakar

“to go and actually buy the doses to treat the kids would have cost tens of millions of dollars that they didn't have in their budget.”

0.63

Before the family's efforts, rare disease was largely ignored by companies, with only one rare disease drug ever approved, and companies focused on statins, AIDS drugs, and oncology.

factualhigh valueestablishednovelty 2/4durability 2/4· Dinakar

“There had been one rare disease drug really ever, and companies were focused on big things at that time”

0.60

Drug development that pursues one idea at a time, moving through candidates sequentially, is too slow for a fast-moving disease; running all plausible ideas in parallel and seeing which work is the faster route.

normativehigh valuespeaker onlynovelty 3/4durability 4/4· Dinakar

“It struck me that we need to do things in parallel processing, not serial processing. If there are five interesting ideas, let's do all five at the same time and see which ones work”

0.57

Singh's team lobbied Washington by enlisting 50 Nobel laureates to sign a letter on SMA's chance of success, and ran full-page color ads in Roll Call and The Hill so staffers would see them daily, because people move faster when they believe others are also engaged.

causalhigh valuespeaker onlynovelty 3/4durability 3/4· Dinakar

“We, for example, got 50 top scientists who are Nobel Prize winners to sign a letter talking about how there was a really good chance of success.”

0.57

Because SMA is a degenerative disease with a single cause, it is now a testbed where muscle-regeneration drugs can be tested, whereas trials in elderly weak patients are confounded by decline and are very hard to run.

causalhigh valuespeaker onlynovelty 3/4durability 3/4· Dinakar

“clinical trials, and this is the problem with Alzheimer's, are very, very challenging in elderly, degenerating patients.”

0.57

Funding and research attention follow disease familiarity rather than need or probability of success: diseases no one has heard of attract few students, grant applicants, or reviewers, so underfunded diseases stay underfunded even when they are as large as well-funded ones.

causalhigh valuespeaker onlynovelty 3/4durability 3/4· Dinakar

“there's pitiful grant money from NIH for this disease, even though other diseases of similar size and a lot less potential probability of success were getting tons of funding. Because, I mean, there is just a latency bias in things.”

0.57

Because academia will not develop drugs, the team built a virtual company: it hired scientists, convened an advisory brain trust, and at periodic reviews asked what must happen next to advance on every front simultaneously.

definitionhigh valuespeaker onlynovelty 3/4durability 3/4· Dinakar

“academia, while very important, was never going to go and develop a drug. And so we really had to create a virtual company.”

0.57

The team offered companies free testing of their compound libraries in its mouse and cell models, letting them keep the IP, because rare-disease work was otherwise so unattractive that companies would not engage even for free.

causalhigh valuespeaker onlynovelty 3/4durability 3/4· Dinakar

“Guys, send your drug libraries in, your compound libraries in, test them for free, we'll pay for it. You keep the IP. We just want you to know if there's something interesting here.”

0.52

Once a parent sees a glimmer of hope for a child's disease, every moment spent at less than maximum speed is wasted, so the parent should pursue the path at full intensity rather than risk finding out later that they moved too slowly.

normativehigh valuespeaker onlynovelty 2/4durability 3/4· Dinakar

“the single worst thing, though, is to see your child suffer and die only to find out that you could have done something about it, but it wasn't done in time.”

0.52

Companies mean well but are trying to attach value to intellectual property rather than solve a disease, so a solution that uses no IP they own is of little use to them, which limits rare-disease progress.

causalhigh valuespeaker onlynovelty 2/4durability 3/4· Dinakar

“companies mean well, but they're not trying to solve a disease, they're trying to attach value to an IP that they have.”

0.52

Academics do not collaborate much and companies avoid collaborating due to IP, and universities increasingly demand IP for royalties, so a neutral third party like Jackson Labs could act as honest broker to coordinate efforts.

normativehigh valuespeaker onlynovelty 2/4durability 3/4· Dinakar

“having a third party that's sort of Switzerland and can be a bit of an honest broker on this stuff is actually pretty important.”

0.52

Singh argues that anger and sorrow are natural for parents but must be channeled into productive efforts, because being consumed by rage achieves nothing for the child.

normativehigh valuespeaker onlynovelty 2/4durability 3/4· Dinakar

“channeling the nettle anger and sorrow into productive channels”

0.52

A parent in tears does not get very far with officials, so advocacy must present a concrete reason to act, namely that the disease might be fixable, not just that it is sad.

normativehigh valuespeaker onlynovelty 2/4durability 3/4· Dinakar Singh

“our view is just a parent with tears on their face doesn't get very far”

0.52

Singh left Goldman to start his fund because the glimmer of hope for saving his daughter would not last, and a large, fast-growing fortune was needed to fund research quickly enough to save her in time.

causalhigh valuespeaker onlynovelty 2/4durability 3/4· Dinakar Singh

“time was not her friend, and so I needed to go as quickly as possible to drive success as quickly as possible”

0.52

Grant funding does not reward scientists for parallel exploration or for ruling out hypotheses, so the grant system discourages the fast elimination of failing ideas that drug discovery needs.

causalhigh valuespeaker onlynovelty 3/4durability 3/4· Dinakar

“You don't get a grant by saying, "I don't think this is going to work, but I just want to prove it doesn't work so I can then move on." That doesn't get you grant money.”

0.52

Treating a disease's symptoms is like bailing water from a boat with a hole; you need to fix the underlying cause first, after which treating downstream symptoms like muscle weakness becomes effective.

normativehigh valuespeaker onlynovelty 3/4durability 3/4· Dinakar

“if you have a boat and you have a hole in it, trying to bail water out of the boat is not really going to be a useful strategy.”

0.51

Singh's team is developing drugs to regenerate muscle and strengthen nerves that could help many patients beyond SMA, because SMA-specific gene drugs are narrow but muscle regeneration applies across diseases, with one candidate already in clinic and three or four more expected.

forecasthigh valuespeaker onlynovelty 3/4durability 2/4· Dinakar Singh

“These regeneration drugs will actually help lots of people.”

0.49

The family spent roughly $150 million of its own money on the SMA effort.

factualhigh valuespeaker onlynovelty 2/4durability 2/4· Dinakar

“I think we spent probably $150 million of our own money on this.”

0.49

Once the hope of a cure was real, any time not spent at maximum speed felt wasted, so Singh chose max-turbo, pull-out-all-stops execution rather than slow, careful development.

normativehigh valuespeaker onlynovelty 2/4durability 2/4· Dinakar Singh

“any second you're spending doing anything that isn't max speed is a wasted moment”

0.49

Singh is building a rare-disease institute with Jackson Labs as a 'Ghostbusters' service: families call, and a team of scientists helps build a game plan regardless of whether the work runs through their organization, because most donors lack a way to make donations effective.

normativehigh valuespeaker onlynovelty 2/4durability 2/4· Dinakar

“our goal is to actually have, I call it the Ghostbusters of rare disease, where if you have a disease, you call us and we'll actually get some scientists to work on it”

0.48

Pitching pharma executives, Singh argued that a rare-disease drug priced at $5,000 to $15,000 a year could generate hundreds of millions of dollars in profit with little development cost, so it need not be a charity project.

forecasthigh valuespeaker onlynovelty 3/4durability 2/4· Dinakar

“if you charge $5,000 to $15,000 a year, you could actually end up with a drug worth hundreds of millions of dollars in profit.”

0.47

Rare-disease cures face a gap between a promising scientific idea and the point where a biotech company will fund development, because companies want evidence of a good chance of cure before committing and early-stage work is still underfunded.

causalhigh valuespeaker onlynovelty 2/4durability 3/4· Dinakar

“there's still too big a gap between a good scientific idea and when a biotech company is actually going to go and spend the money and do it.”

0.47

Companies now care about rare diseases because the money from SMA has been visible, but the challenge is that rare diseases are bespoke, so investors still need to be convinced of a real chance of cure, unlike oncology work that persists for decades.

causalhigh valuespeaker onlynovelty 2/4durability 3/4· Dinakar

“you don't need to convince someone that it could eventually be very profitable, but you still have to convince them that there's a good chance that they'll be able to go and cure it.”

0.40

The family's daughter was diagnosed with spinal muscular atrophy a month after 9/11, when the disease was little understood because its gene had only been discovered a few years earlier and it was often thought to be a variant of muscular dystrophy.

factualestablishednovelty 1/4durability 4/4· Dinakar

“The gene for it was just discovered a few years before, and until then, people thought it was just a variant of muscular dystrophy or some other muscle disease.”

0.38

SMA families face a spiral in which parents lose jobs from repeated time off for care and cannot afford insurance, and in one example a Walmart worker with twins with SMA had to face that spiral.

factualestablishednovelty 1/4durability 2/4· Dinakar

“Parents who lose their jobs because they keep taking time off and they can't afford the insurance”

0.36

The family paid PTC Therapeutics to screen widely, and the screen found a small-molecule drug that worked well, which was later developed with Roche and is the drug the daughter takes now.

factualestablishednovelty 2/4durability 2/4· Dinakar

“We basically paid a company called PTC Therapeutics lots and lots of money to go and test everything under the sun”

0.33

Government did a good job in some areas and can be made smarter, and government or institutions like Jackson Labs can play a coordinated role in picking a few diseases and funding them modestly, rather than abandoning public support altogether.

normativecontestednovelty 2/4durability 2/4· Dinakar Singh

“Government did a pretty good job in some of the stuff, but certainly we can make government smarter.”

0.31

Top drug developers gave their time for free, joining a brain trust for a couple of weekends a year, because neurology had been a graveyard with no meaningful drug for decades and the project offered a real chance to fund and test a plan.

factualspeaker onlynovelty 2/4durability 2/4· Dinakar Singh

“we would get a dozen and a half of the smartest drug development people in the entire world coming together for a couple weekends a year”

0.30

Parents of children with severe disease sustain themselves through community and peer support, which channels grief and anger into productive advocacy and makes families stronger than they would be as isolated individuals.

normativespeaker onlynovelty 1/4durability 3/4· Dinakar

“we've come to realize how much deeper our reserves of strength are as part of community than as individuals.”

0.26

Singh's daughter, a wheelchair user, was rejected by most New York City private schools despite accessible facilities, with one school citing her intelligence and another requesting medical records, showing how disability stigma operates even among well-connected families.

factualspeaker onlynovelty 1/4durability 2/4· Dinakar

“I couldn't find a single school that would take her.”

0.26

A top biotech executive dismissed the pitch, arguing that because Avastin was the most expensive drug at $50,000 a year, no one would pay that much for a small pediatric rare disease.

factualspeaker onlynovelty 2/4durability 2/4· Dinakar

“the most expensive drug in the world is Avastin, which was an oncology drug at $50,000 a year. No one's ever going to pay that kind of money for a small rare disease for children.”

0.26

Singh claims that no drug has ever been developed without using mice from Jackson Laboratory, making it arguably the most important biotech institution that few have heard of.

factualspeaker onlynovelty 2/4durability 2/4· Dinakar

“no drug has ever been developed without using their mice”

0.26

Only perhaps six people in the country deeply understand muscle biology, including muscle stem cells called satellite cells, despite the assumption that big money and many experts would be working on it.

factualspeaker onlynovelty 2/4durability 2/4· Dinakar Singh

“There may be six people in this country that know what they're talking about when it comes to muscle.”

0.26

The first SMA drug may have been the fastest FDA approval of any drug in history, a result Singh attributed to persistent advocacy and the regulatory design choices made during development.

factualspeaker onlynovelty 2/4durability 2/4· Dinakar

“the first SMA drug, I think, was then, and maybe still now, the fastest approval by the FDA ever in history of any drug.”

0.24

Singh named TPG-Axon after the axon, the nerve that connects brain to muscle and degenerates in spinal muscular atrophy, so the name would remind him of the mission to save his daughter.

definitionspeaker onlynovelty 0/4durability 4/4· Dinakar

“The axon is the nerve that connects your brain to your muscle and it happens to be the core part of what degenerates in spinal muscular atrophy”

0.24

Compassion from friends and strangers, such as hugs after a diagnosis, gives people the strength to stand up and move forward the next day during their worst moments.

normativespeaker onlynovelty 0/4durability 4/4· Dinakar

“I think in life at our worst moments, just getting some of people's strength and energy imbued in you a little bit gives you the ability to go and stand up and move forward the next day.”

0.24

Singh argues that while circumstances are not chosen, whether one finds joy and purpose in them is ultimately up to the individual, and that the magnitude of joy from small things can equal joy from expected things.

normativespeaker onlynovelty 1/4durability 2/4· Dinakar

“whether you choose to find joy and purpose in them is very much ultimately up to you”

0.22

Novartis's compound had failed development for toxicity in an unrelated indication decades earlier but turned out to be highly effective against SMA when tested, which changed companies' view of the disease.

factualspeaker onlynovelty 2/4durability 1/4· Dinakar

“they ended up finding a drug that had failed for tox reasons, for anorexia or something back in the 70s that was off the charts good”

0.22

NIH launched its first translational research grants aimed at drug discovery and picked SMA as a target, but leadership turnover left acting directors at NIH and NINDS, and the program produced little real progress.

factualspeaker onlynovelty 2/4durability 1/4· Dinakar

“The head of NIH stepped down and the head of NINDS, the Neurological Institute, stepped down. And so you had acting directors in both places.”

0.21

Singh argues the family's work matters more for the lives and families of 20,000 affected children than for the economic value of the drug.

normativespeaker onlynovelty 1/4durability 2/4· Dinakar

“to say nothing of that being a footnote compared to the impact it has on the lives and the families”

0.21

Singh's daughter began the first SMA drug at age 12 and has been stable since, though earlier treatment would have been better and she remains fragile.

factualspeaker onlynovelty 1/4durability 2/4· Dinakar Singh

“My daughter ended up being on the first drug since she was 12, has been stable since then”

0.21

Singh's background in a scientist family combined with finance expertise allowed the family to apply science to the SMA problem with resources, a combination he presents as the source of the effort's leverage.

factualspeaker onlynovelty 1/4durability 2/4· Dinakar

“having some of the science background, but having the good fortune and the good luck and privilege of working in investing and finance, helped us go and actually put that science to work further.”

0.14

Singh mentions that Val Kilmer died of pneumonia, which was a side effect of throat cancer in his case.

factualestablishednovelty 0/4durability 0/4· Dinakar

“Val Kilmer just died yesterday of pneumonia”